IL161233A0 - Fragments of the polypeptide gzip and their use in obesity - Google Patents

Fragments of the polypeptide gzip and their use in obesity

Info

Publication number
IL161233A0
IL161233A0 IL16123302A IL16123302A IL161233A0 IL 161233 A0 IL161233 A0 IL 161233A0 IL 16123302 A IL16123302 A IL 16123302A IL 16123302 A IL16123302 A IL 16123302A IL 161233 A0 IL161233 A0 IL 161233A0
Authority
IL
Israel
Prior art keywords
metabolic
obesity
disorders
gzip
polypeptide
Prior art date
Application number
IL16123302A
Other languages
English (en)
Original Assignee
Genset Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genset Sa filed Critical Genset Sa
Publication of IL161233A0 publication Critical patent/IL161233A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL16123302A 2001-10-05 2002-10-03 Fragments of the polypeptide gzip and their use in obesity IL161233A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32772501P 2001-10-05 2001-10-05
PCT/IB2002/004598 WO2003050281A2 (en) 2001-10-05 2002-10-03 Fragments of the human zn-alpha2-glycolprotein and their use in methods of treatment of obesity

Publications (1)

Publication Number Publication Date
IL161233A0 true IL161233A0 (en) 2004-09-27

Family

ID=23277766

Family Applications (2)

Application Number Title Priority Date Filing Date
IL16123302A IL161233A0 (en) 2001-10-05 2002-10-03 Fragments of the polypeptide gzip and their use in obesity
IL161233A IL161233A (en) 2001-10-05 2004-04-01 Method for screening for an antagonist

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL161233A IL161233A (en) 2001-10-05 2004-04-01 Method for screening for an antagonist

Country Status (11)

Country Link
US (1) US7402393B2 (cg-RX-API-DMAC7.html)
EP (1) EP1432803B1 (cg-RX-API-DMAC7.html)
JP (1) JP4423038B2 (cg-RX-API-DMAC7.html)
AT (1) ATE380868T1 (cg-RX-API-DMAC7.html)
AU (1) AU2002339678B2 (cg-RX-API-DMAC7.html)
CA (1) CA2461491A1 (cg-RX-API-DMAC7.html)
DE (1) DE60224064T2 (cg-RX-API-DMAC7.html)
DK (1) DK1432803T3 (cg-RX-API-DMAC7.html)
ES (1) ES2295415T3 (cg-RX-API-DMAC7.html)
IL (2) IL161233A0 (cg-RX-API-DMAC7.html)
WO (1) WO2003050281A2 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1509545B8 (en) 2002-05-31 2010-10-13 Merck Serono Biodevelopment SAS Homotrimeric extended obg3 globular head and uses thereof
AU2003299378A1 (en) * 2002-10-11 2004-05-04 Board Of Regents, The University Of Texas System Method and compounds for inhibiting hec1 activity for the treatment of proliferative diseases
EP1548445A3 (en) * 2003-12-22 2005-11-23 F. Hoffmann-La Roche Ag Novel targets for obesity from fat tissue
US20100173829A1 (en) * 2008-11-07 2010-07-08 Aston University Glycoproteins Having Lipid Mobilizing Properties and Therapeutic Uses Thereof
US8892184B2 (en) 2010-10-18 2014-11-18 Siemens Medical Solutions Usa, Inc. Systems and methods for reducing interference in a dual modality imaging system
JP2015524808A (ja) * 2012-07-25 2015-08-27 ユニバーシティ・オブ・シンシナティ アポリポタンパク質ａｉｖを用いたｉ型糖尿病の治療法
US11213567B2 (en) * 2017-09-29 2022-01-04 L&C Bio Co., Ltd. ZAG-derived peptide and use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9811465D0 (en) * 1998-05-29 1998-07-29 Tisdale Michael J Glycoproteins having lipid mobilising properties and therapeutic applications thereof
BR0107626A (pt) * 2000-01-14 2002-10-15 Genset Sa Cabeças globulares de obg3 e usos destes para diminuir a massa corporal
CA2462588A1 (en) * 2001-10-12 2003-04-24 Genset S.A. Ngzipa, ngzipd, pgzipa, and pgzipd polynucleotides and polypeptides and uses thereof

Also Published As

Publication number Publication date
DK1432803T3 (da) 2008-03-10
AU2002339678B2 (en) 2007-10-25
JP4423038B2 (ja) 2010-03-03
DE60224064T2 (de) 2008-11-20
DE60224064D1 (de) 2008-01-24
AU2002339678B8 (en) 2003-06-23
US7402393B2 (en) 2008-07-22
US20070054845A1 (en) 2007-03-08
AU2002339678A1 (en) 2003-06-23
CA2461491A1 (en) 2003-06-19
EP1432803B1 (en) 2007-12-12
JP2005511088A (ja) 2005-04-28
IL161233A (en) 2010-05-17
EP1432803A2 (en) 2004-06-30
WO2003050281A2 (en) 2003-06-19
WO2003050281A3 (en) 2003-12-04
ATE380868T1 (de) 2007-12-15
ES2295415T3 (es) 2008-04-16

Similar Documents

Publication Publication Date Title
WO2003057666A3 (en) Inhibitors of dipeptidyl peptidase iv
PT1248849E (pt) Cabeça globular obg3 e suas utilizações para reduzir a massa corporal
WO2001013906A3 (en) Compositions including modafinil for treatment of eating disorders and for appetite stimulation
MXPA04003796A (es) Tioacetamidas sustituidas.
ATE356607T1 (de) Verwendung von nativem zein zur verbesserung des haarzustandes und mittel
MXPA02011288A (es) Tioacetamidas substituidas.
AU2003259706A1 (en) Therapeutic process for the treatment of obesity and associated metabolic disorders
SG160205A1 (en) Modified polypeptide
WO2001070737A3 (en) Therapeutic heterocyclic compounds for the treatment of asthma and allergy and use thereof
WO2003010314A3 (en) Gmg-2 polynucleotides and polypeptides and uses thereof
WO2003050281A3 (en) Fragments of the human zn-alpha2-glycolprotein and their use in methods of treatment of obesity
WO2004032850A3 (en) Uses of human zven antagonists
WO2003010197A3 (en) Gmg-1 polynucleotides and polypeptides and uses thereof
WO2003033534A3 (en) Ngzipa, ngzipd, pgzipa, and pgzipd polynucleotides and polypeptides and uses thereof
ATE491442T1 (de) 1-phenyl-2- dimethylaminomethylcyclohexanverbindungen zur therapie von depressiven symptomatiken, schmerz und inkontinenz
WO2002066505A3 (en) Gmg-3, gmg-4, and gmg-6 polynucleotides and polypeptides and uses thereof
WO2002060466A3 (en) Gssp3 polynucleotides and polypeptides and uses thereof
WO2003082915A3 (en) Xcrf polynucleotides and polypeptides and uses thereof
WO2003051911A3 (en) Gmg-5 polynucleotides and polypeptides and uses thereof
WO2002055694A3 (en) Discriminative nucleic acid analysis using clone sequence signatures
WO2004031354A3 (en) Human sarcoma-associated antigens
AU2002307819A1 (en) Gssp4 polynucleotides and polypeptides and uses thereof
AU2002348299A8 (en) Methods and compositions for the treatment of pain and other hormone-allergy-related symptoms using dilute hormone solutions
WO2003095485A3 (en) Krib polynucleotides and polypeptides and uses thereof in the treatment of metabolic disorders
IL132354A0 (en) Use of cartilage oligomeric matrix protein for the treatment of rheumatoid arthritis